FDA Approves Pembrolizumab for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer
Efficacy was evaluated in KEYNOTE-057 trial
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Efficacy was evaluated in KEYNOTE-057 trial
Consensus recommendations from the EORTC and ESTRO’s Cancer OligoCare project
It also approved the BRACAnalysis CDx test as a companion diagnostic
Evidence for efficacy was evaluated in the ARCHES trial
It is the first Nectin-4-directed antibody-drug conjugate to receive FDA approval
Efficacy was evaluated in the DESTINY-Breast01 trial
New indication concerns combination with erlotinib for the first-line treatment of adult patients with metastatic NSCLC with activating EGFR mutations
Positive opinion is related to a new pharmaceutical form associated with a new strength and a new route of administration
It binds to the myristoyl pocket, a previously unexploited feature of ABL1 and ABL2 kinases
New indication concerns the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy
ESMO is sad to learn of the death of Professor Pierre Alberto, a wise and thoughtful oncologist whose clinical innovations and educational initiatives had a lasting impact.
Results from the studies with tucatinib, trastuzumab deruxtecan in patients with metastatic breast cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.